Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure N.V. reports company news on its gene therapy pipeline, regulatory interactions, clinical data, operating results, and capital structure. The company develops genetic medicines for severe diseases, with disclosed programs including AMT-130 for Huntington’s disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease, ALS programs, and an approved gene therapy for hemophilia B.
Recurring updates cover FDA and MHRA discussions, clinical-trial observations, exploratory efficacy and safety data, quarterly and annual financial results, debt financing arrangements, corporate presentations, and governance or shareholder matters tied to its Nasdaq-listed public-company status.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
uniQure N.V. (NASDAQ: QURE) announced the granting of equity awards to 31 employees to incentivize their employment, as per Nasdaq Listing Rule 5635(c)(4). The awards include 63,300 restricted share units (RSUs) and options for 57,500 ordinary shares, with an exercise price of $20.06, reflecting the closing price on the grant date of February 23, 2023. Options will vest over four years, with one-quarter vesting after the first year and the remainder in quarterly installments. RSUs will vest over three years. This initiative is part of uniQure's strategy to attract talent as it advances its gene therapy pipeline targeting severe diseases.
uniQure N.V. (NASDAQ: QURE) announced its participation in various investor and scientific conferences in March 2023. Key events include the Cowen Annual Healthcare Conference from March 6-8 in Boston, where CEO Matt Kapusta will engage in one-on-one meetings and a panel discussion.
Other conferences include the Bioprocessing Summit Europe on March 15 in Barcelona, the Huntington's Disease Youth Organization Congress from March 17-19 in Glasgow, and the MDA Conference from March 19-22 in Austin. The company aims to showcase its advancements in gene therapy, particularly for severe medical conditions like hemophilia B.
uniQure N.V. (NASDAQ: QURE) announced significant milestones, including U.S. and European marketing approvals for HEMGENIX®, the first gene therapy for hemophilia B. The company is advancing AMT-130 for Huntington’s disease, with updates expected in Q2 2023. Plans for new clinical trials for AMT-260 (temporal lobe epilepsy) and AMT-162 (SOD1 ALS) are set for the second half of 2023. Financial results show a revenue decline to $106.5 million in 2022, down from $524 million in 2021, with a net loss of $126.8 million. The company holds $392.8 million in cash, expected to fund operations into 2025, contingent on milestone payments for HEMGENIX®.